Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Cyclosporine may slow down how quickly your liver processes your cholesterol medicine.
What might happen:
The amount of cholesterol medicine in your blood may increase and cause muscle problems, such as muscle aches, tenderness, or weakness.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these medicines together. Your doctor may want to change your cholesterol medicine. Let your doctor know right away if you have any muscle aches, tenderness, or weakness.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004 Aug;76(2):167-77.
- 2.Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006 Dec; 80(6):565-81.
- 3.Yang WH, Zeng ZS, Ren XW, Li YP, Shang WJ, Feng GW, Zhang LR. Simvastatin-induced myopathy with concomitant use of cyclosporine: case report. Int J Clin Pharmacol Ther 2011 Dec;49(12):772-7.
- 4.Lescol (fluvastatin sodium) US prescribing information. Novartis Pharmaceuticals Corporation October, 2012.
- 5.Pravachol (pravastatin sodium) US prescribing information. Bristol-Myers Squibb Company September, 2020.
- 6.Crestor (rosuvastatin calcium) US prescribing information. AstraZeneca Pharmaceuticals LP September, 2020.
- 7.Park JW, Siekmeier R, Merz M, Krell B, Harder S, Marz W, Seidel D, Schuler S, Gross W. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther 2002 Oct;40(10):439-50.
- 8.Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997 Sep;62(3):311-21.
- 9.Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol 1999; 19(3):411-5.
- 10.Akhlaghi F, McLachlan AJ, Keogh AM, Brown KF. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997 Dec;44(6):537-42.
- 11.Holdaas H, Hagen E, Asberg A, Lund K, Hartman A, Vaidyanathan S, Prasad P, He YL, Yeh CM, Bigler H, Rouilly M, Denouel J. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 2006 Apr; 44(4):163-71.
- 12.Locsey L, Asztalos L, Kincses Z, Balazs G. Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants. Int Urol Nephrol 1997;29(1):95-106.
- 13.Li PK, Mak TW, Chan TH, Wang A, Lam CW, Lai KN. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation 1995 Oct 15;60(7):652-6.
- 14.Holdaas H, Hartmann A, Stenstrom J, Dahl KJ, Borge M, Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995 Jul 13; 76(2):102A-106A.
- 15.Li PK, Mak TW, Wang AY, Lee YT, Leung CB, Lui SF, Lam CW, Lai KN. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther 1995 Apr;33(4):246-8.
- 16.Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schuler S, Jaross W. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 2001 Oct; 6(4):351-61.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.